Glutathione S-transferase O2 Gene Rs157077 Polymorphism Predicts Response to Transarterial Chemoembolization in Hepatocellular Carcinoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Apr 4

PMID 25835968

Citations 4

Authors

Zhixin Wang

Kai Qu

Zhichao Huang

Xinsen Xu

Jingyao Zhang

Li Zhang

Sinan Liu

Hulin Chang

Ting Lin

Yamin Liu

Wenquan Niu

Chang Liu

Affiliations

Soon will be listed here.

Abstract

Some genetic alterations of glutathione S-transferase omega 2 (GSTO2) have been reported to increase the risk of many malignancies, including hepatocellular carcinoma (HCC); however, their prognostic capability remained unresolved in HCC patients treated with transarterial chemoembolization (TACE). To fill this gap, we genotyped three well-defined polymorphisms in GSTO2 to assess whether they can predict overall survival among 228 HCC patients under TACE treatment. The median follow-up time and survival time were 22.0 months (range 3.0-60.0) and 19.2 months, respectively. Only one of three polymorphisms examined, rs157077, was significantly associated with overall survival of TACE-treated HCC (P = 0.003), and its mutant allele conferred a higher risk of death than its wild homozygotes (hazard ratio 1.58, 95 % confidence interval 1.17-2.14). Moreover, carriers of this mutant allele had higher tissue GSTO2 expression, reinforcing the prognostic capability of GSTO2 rs157077 for HCC, especially in combination with age and tumor-node-metastasis (TNM) stage. Taken together, we for the first time provided evidence supporting the prognostic role of GSTO2 in the progression of TACE-treated HCC.

Citing Articles

Glutathione -transferase π: a potential role in antitumor therapy.

Dong S, Sha H, Xu X, Hu T, Lou R, Li H Drug Des Devel Ther. 2018; 12:3535-3547.

PMID: 30425455 PMC: 6204874. DOI: 10.2147/DDDT.S169833.

The status of transarterial chemoembolization treatment in the era of precision oncology.

Fako V, Wang X Hepat Oncol. 2017; 4(2):55-63.

PMID: 28989699 PMC: 5618739. DOI: 10.2217/hep-2017-0009.

Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma.

Lu Y, Yao J, Huang X, Wang C, Wu X, Xia Q Sci Rep. 2016; 6:36104.

PMID: 27796321 PMC: 5086876. DOI: 10.1038/srep36104.

Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study.

Wang Z, Qu K, Niu W, Lin T, Xu X, Huang Z Tumour Biol. 2015; 37(1):943-52.

PMID: 26260272 DOI: 10.1007/s13277-015-3871-7.

References

Cho E, Kim H, Lee J, Yoo J, Choi W, Cho Y . Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization. PLoS One. 2014; 9(3):e90862. PMC: 3942491. DOI: 10.1371/journal.pone.0090862. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Zheng Y, Meng Q, Zhao W, Liu B, Huang J, He X . Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014; 31(3):843. DOI: 10.1007/s12032-014-0843-5. View

Zhang Y, Chen Y, Ahsan H, Lunn R, Chen S, Lee P . Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett. 2005; 221(2):135-43. DOI: 10.1016/j.canlet.2004.08.028. View

Whitbread A, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board P . Characterization of the omega class of glutathione transferases. Methods Enzymol. 2006; 401:78-99. DOI: 10.1016/S0076-6879(05)01005-0. View

Xu Y, Wang J, Yin R, Qiu M, Xu L, Wang J . Genetic polymorphisms in Glutathione S-transferase Omega (GSTO) and cancer risk: a meta-analysis of 20 studies. Sci Rep. 2014; 4:6578. PMC: 4192632. DOI: 10.1038/srep06578. View

Board P, Coggan M, Chelvanayagam G, Easteal S, Jermiin L, Schulte G . Identification, characterization, and crystal structure of the Omega class glutathione transferases. J Biol Chem. 2000; 275(32):24798-806. DOI: 10.1074/jbc.M001706200. View

Mukherjee B, Salavaggione O, Pelleymounter L, Moon I, Eckloff B, Schaid D . Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos. 2006; 34(7):1237-46. DOI: 10.1124/dmd.106.009613. View

Liu L, Zhao L, Zhang Y, Zhang Q, Ding Y . Proteomic analysis of Tiam1-mediated metastasis in colorectal cancer. Cell Biol Int. 2007; 31(8):805-14. DOI: 10.1016/j.cellbi.2007.01.014. View

10.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48(5):599-641. DOI: 10.1016/j.ejca.2011.12.021. View

11.

Marahatta S, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S . Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett. 2005; 236(2):276-81. DOI: 10.1016/j.canlet.2005.05.020. View

12.

Lee W, Morton R, Epstein J, Brooks J, Campbell P, Bova G . Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994; 91(24):11733-7. PMC: 45306. DOI: 10.1073/pnas.91.24.11733. View

13.

Giri U, Terry N, Kala S, Lieberman M, Story M . Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28). Cancer Chemother Pharmacol. 2005; 55(6):511-21. DOI: 10.1007/s00280-004-0920-0. View

14.

Niu D, Zhang J, Ren Y, Feng H, Chen W . HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol Oncol. 2009; 3(1):67-76. PMC: 5527876. DOI: 10.1016/j.molonc.2008.10.002. View

15.

Masoudi M, Saadat I, Omidvari S, Saadat M . Association between N142D genetic polymorphism of GSTO2 and susceptibility to colorectal cancer. Mol Biol Rep. 2010; 38(7):4309-13. DOI: 10.1007/s11033-010-0555-7. View

16.

OSuilleabhain C, Poon R, Yong J, Ooi G, Tso W, Fan S . Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003; 90(3):325-31. DOI: 10.1002/bjs.4045. View

17.

Chung J, Naik N, Lewandowski R, Deng J, Mulcahy M, Kulik L . Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol. 2010; 16(25):3161-7. PMC: 2896753. DOI: 10.3748/wjg.v16.i25.3161. View

18.

Pongstaporn W, Pakakasama S, Sanguansin S, Hongeng S, Petmitr S . Polymorphism of glutathione S-transferase Omega gene: association with risk of childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol. 2008; 135(5):673-8. DOI: 10.1007/s00432-008-0501-4. View

19.

Chasseaud L . The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res. 1979; 29:175-274. DOI: 10.1016/s0065-230x(08)60848-9. View

20.

Xu X, Qu K, Liu C, Zhang Y, Liu J, Song Y . Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol. 2013; 18(48):7242-50. PMC: 3544026. DOI: 10.3748/wjg.v18.i48.7242. View